TBC
TBC
Validation Strategies for Pharmaceutical Patents in Europe
Special Report
The decision on where to validate a pharmaceutical European patent is a big one. With costs often precluding an “everywhere” approach for small- to medium-sized companies, research institutions and universities, it is necessary to choose from the long list of available countries. The choice typically factors in costs, business interests, likely markets and market size, possible manufacturing and import locations and the regulatory framework in Europe.
This report explores these choices and factors using publicly available data, seeking to answer questions such as:
- Which countries are most commonly picked by patent holders at the EPO?
- Is the distribution the same for pharmaceutical patents?
- Where does “big pharma” choose to validate?
- What factors might affect the choice of countries?
Read our blogs
Patent Strategies for Cell-based Therapeutics
Securing robust patent protection for cell-based therapeutics presents unique challenges, particularly before the European Patent Office (EPO). As the field of regenerative medicine and cell therapy ...
Mitochondria: the secret to regenerating human tissue?
Istesso co-founder Lisa Patel is researching how to regenerate and repair tissue by modulating mitochondria. The method has the potential to treat multiple diseases of ageing, such as arthritis, ...
Bispecific antibodies: A new way to combat drug resistance
Biotech veteran Dr Rob Arathoon is pioneering a new way to counteract multi-drug resistance in cancer using bispecific antibodies. He explains his work.
Ozempic and the Anti-Ageing Opportunity
Semaglutide, a GLP-1 receptor agonist (GLP-1RA) best known by its brand names Ozempic and Wegovy, has already reshaped the treatment landscape for type 2 diabetes and obesity. However, compelling new ...
-1.png)
Are proprietors out of luck on appeal? It’s all in the reporting
The 2024 EPO Boards of Appeal Annual Report has recently been published, and, once again, it’s the appeal success statistics that are drawing the attention of patent applicants, proprietors, and ...
Most Active Visible Opponents at the EPO in 2024
An opposition is a formal request for revocation of a patent, which can be filed by a third party within nine months of patent’s grant by the European Patent Office.
Mewburn Ellis
FORWARD MAGAZINE
Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.